{"entity":{"id":"symbiotic-gi-03","kind":"trial","name":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","aka":["Symbiotic-GI-03"],"tldr":"A phase 3 trial testing PF-08634404 in colorectal cancer, now recruiting.","summary":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07222800, led by Pfizer, and recruiting on the registry. Official title: An interventional, phase 3, double-blind, randomised study to evaluate the efficacy and safety of PF-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer. Planned enrolment is 800 participants (estimated). The study started in 2025-12-11 and primary completion is expected in 2030-03-29. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07222800","url":"https://clinicaltrials.gov/study/NCT07222800"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["pf-08634404"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07222800","phase":"3","setting":"An interventional, phase 3, double-blind, randomized study to evaluate the efficacy and safety of PF-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer","sponsor":"Pfizer","participation":[{"nct":"NCT07222800","source":"https://clinicaltrials.gov/study/NCT07222800","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"a17817c2900a9066aa3f471a8a641ffccd58c5c881e589e4fa64daf2cbd61994","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"Pfizer","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":800,"enrolmentType":"ESTIMATED","siteCount":348,"recruitingSiteCount":332,"countries":["Argentina","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Israel","Italy","Japan","Poland","Puerto Rico","Spain","Taiwan","United States"]}],"started":"2025-12-11","startedType":"actual","enrolled":800,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/symbiotic-gi-03/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}